Lara Sullivan exit package at Pyxis Oncology (NASDAQ: PYXS)
Filing Impact
Filing Sentiment
Form Type
8-K/A
Rhea-AI Filing Summary
Pyxis Oncology, Inc. filed an amendment to outline the separation terms for Lara Sullivan, M.D., whose service as Chief Executive Officer and principal executive officer ended earlier in 2026. The filing also notes that she resigned from the Board of Directors on April 29, 2026, and that her resignation was not due to any dispute or disagreement over the company’s operations or policies.
Under a Separation and General Release Agreement effective April 29, 2026, Dr. Sullivan will receive her existing salary for 18 months and may continue health coverage for up to 12 months. All of her unvested restricted stock units and stock options will vest, and the period to exercise her stock options is extended to December 31, 2030. The agreement includes a one-year post-separation non-solicitation covenant for Dr. Sullivan and a one-year mutual non-disparagement covenant.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Salary continuation period: 18 months
Health coverage continuation: 12 months
Option exercise extension: December 31, 2030
+3 more
6 metrics
Salary continuation period
18 months
Existing salary payable after Effective Date of April 29, 2026
Health coverage continuation
12 months
Continued health coverage for up to 12 months after Effective Date
Option exercise extension
December 31, 2030
New end date for post-termination exercise of accelerated stock options
Non-solicitation period
1 year
Post-separation non-solicitation covenant for Lara Sullivan
Non-disparagement period
1 year
Post-separation non-disparagement covenant for both parties
Effective date of agreement
April 29, 2026
Date the Separation and General Release Agreement became binding
Key Terms
Separation and General Release Agreement, accelerated vesting, restricted stock units, non-solicitation covenant, +1 more
5 terms
Separation and General Release Agreement financial
"This Amendment No. 1 ... to report a Separation and General Release Agreement"
accelerated vesting financial
"approved the accelerated vesting of all unvested restricted stock units"
restricted stock units financial
"accelerated vesting of all unvested restricted stock units and unvested stock options"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
non-solicitation covenant financial
"provides for a one-year post-separation non-solicitation covenant"
A non-solicitation covenant is a contract clause that stops one party from actively recruiting or doing business with the other party’s employees, customers or suppliers for a set time. Think of it as a temporary “do not lure” rule that protects relationships and team members after a deal or employment change. For investors, it reduces the risk that key staff or clients will be poached, helping protect revenue, integration plans and the value of the investment.
non-disparagement covenant financial
"a one-year post-separation non-disparagement covenant applicable to both parties"
FAQ
What does Pyxis Oncology (PYXS) disclose in this 8-K/A amendment?
Pyxis Oncology details a Separation and General Release Agreement with former CEO Lara Sullivan, M.D. It covers salary continuation, health benefits, accelerated equity vesting, extended option exercise rights, and one-year non-solicitation and non-disparagement covenants effective April 29, 2026.
Why did Lara Sullivan leave Pyxis Oncology (PYXS) and its board?
The filing states that Lara Sullivan, M.D. ceased serving as CEO and principal executive officer earlier in 2026 and resigned from the Board on April 29, 2026. Her resignation was expressly noted as not resulting from any dispute or disagreement with Pyxis Oncology or its Board.
What severance benefits will former CEO Lara Sullivan receive from Pyxis Oncology (PYXS)?
Under the Separation Agreement, Lara Sullivan will receive her existing salary for 18 months and may continue health coverage for up to 12 months after April 29, 2026. These benefits are part of a negotiated separation package between her and Pyxis Oncology.
How are Lara Sullivan’s stock awards treated in the Pyxis Oncology (PYXS) separation?
All unvested restricted stock units and unvested stock options previously granted to Lara Sullivan will vest. The period to exercise her accelerated stock options is extended to December 31, 2030, giving her additional time to decide whether to exercise those awards.
What restrictive covenants are included in Lara Sullivan’s agreement with Pyxis Oncology (PYXS)?
The Separation Agreement includes a one-year post-separation non-solicitation covenant applying to Lara Sullivan and a one-year post-separation non-disparagement covenant applying to both her and Pyxis Oncology. These provisions govern how the parties interact with employees and speak about each other after separation.
When did Lara Sullivan’s Separation Agreement with Pyxis Oncology (PYXS) become effective?
The Separation and General Release Agreement between Pyxis Oncology and Lara Sullivan became binding and effective on April 29, 2026. That same date is referred to as the Effective Date and is when her Board resignation also took effect, according to the filing.